NKTR News and Press, Nektar Therapeutics From 03/14/22

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Biopharmaceutical company Nektar Therapeutics (NASDAQ: NKTR ) is down big today after announcing disappointing results regarding its melanoma therapy. The news clearly displeased Nektar investors. NKTR stock has shed ...

Gainers: Volt Information Sciences (NYSE:VOLT) +96%. Red Cat Holdings (OTCQB:RCAT) +46%. Turquoise Hill Resources (NYSE:TRQ) +32%. Zhongchao (NASDAQ:ZCMD) +29%. Mullen Automotive (NASDAQ:MULN) +28%. AgriFORCE Growing Systems (NASDAQ:AGRI) +26%. FirstMark Horizon Acquisition (NYSE:FMAC) +23%. ...

Shares of Nektar Therapeutics (NASDAQ: NKTR) , a biopharmaceutical company developing new cancer drugs, are getting crushed today after the company reported a disappointing clinical trial failure. The stock was down 56% as of 11:28 a.m. ET on Monday. Nektar has several commercia...

Clinical-stage biotech Nektar Therapeutics (NKTR -55.0%) continues to trade sharply lower on Monday after the company announced its lead candidate bempegaldesleukin failed to meet the main goals in a late-stage study in melanoma in combination with Opdivo from Bristol Myers (NYSE:BMY). I...

Gainers: Zhongchao (NASDAQ:ZCMD) +35%. Moderna (NASDAQ:MRNA) +15%. ERYTECH Pharma (NASDAQ:ERYP) +14%. Allied Healthcare Products (NASDAQ:AHPI) +13%. 4D pharma (NASDAQ:LBPS) +13%. Losers: Nektar Therapeutics (NASDAQ:NKTR) -53%. MultiPlan (NYSE:MPLN) -26%. ...

Clinical-stage biotech, Nektar Therapeutics (NKTR -2.7%) has lost more than 53% in the pre-market Monday after the company and Bristol Myers Squibb (NYSE:BMY) announced a major setback for its lead immuno-oncology candidate bempegaldesleukin in a late-stage trial for melanoma. The P...

Nektar Therapeutics (NASDAQ:NKTR) -49% after phase 3 trial in skin cancer with Bristol Myers fails. Electric Last Mile Solutions (NASDAQ:ELMS) -31%. Marine Petroleum (NASDAQ:MARPS) -23%. Enservco (NYSE:ENSV) -20%. Hycroft Mining Holding (NASDAQ:HYMC) -19%. Excellon Resources (NYSE:E...

Bristol Myers Squibb (NYSE:BMY) and Nektar Therapeutics' (NASDAQ:NKTR) phase 3 trial evaluating bempegaldesleukin in combination with Opdivo (nivolumab) against Opdivo alone as a first-line treatment for previously untreated unresectable or metastatic melanoma did not meet the main ...

Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Announcement of Update from Bristol-Myers Squibb and Nektar on the PIVOT-IO-001 Phase 3 Trial Nektar Therapeutics to Host Webcast Conference Call for Analysts & Investors Following Ann...

Bristol Myers Squibb (NYSE: BMY) and Nektar Therapeutics (NASDAQ: NKTR) today announced an update following the first analysis of the Phase 3 PIVOT IO-001 study evaluating the doublet therapy of bempegaldesleukin in combination with Opdivo (nivolumab) compared to Opdivo ...